About Nextech Venture
Nextech Venture is a venture capital firm founded in 1998. It is primarily based out of Zurich, Switzerland. As of Mar 2024, Nextech Venture has invested in 8 companies. It primarily invests in Series D round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Consumer. Most recently it participated in the $***** Series C round of Alumis Overall, Nextech Venture portfolio has seen 3 IPOs and 3 acquisitions including key companies like Alumis, MacroGenics and Ganymed Pharmaceuticals. A lot of funds co-invest with Nextech Venture, with names like HBM Healthcare Investments sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series D & 4 more
Portfolio IPOs
Portfolio Acquisitions
Nextech Venture's List of Top Investments
Nextech Venture has a portfolio of 8 companies. Their most notable investmentis in MacroGenicsTheir portfolio spans across United States, Germany, Switzerland and 1 more locations. They have invested in Life Sciences, High Tech, Consumer and 1 other sectors, across stages such as Series A, Series D and 4 more. Here is the list of top investments by Nextech Venture:
1. Alumis
Developer of therapeutics for the treatment of auto-immune disease. The lead candidate SK-001 is a potentially best-in-class TYK2 inhibitor for psoriasis treatment. The TYK2 is a gene that encodes a member of the tyrosine kinase which is a key mediator of inflammation and autoimmune diseases.
Key facts about Alumis
- Founded Year: 2003
- Location: San Francisco (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $529M
- Employee Count: 254 as on Jul 31, 2026
- Investors: Foresite Capital, VenBio and 15 Others
- Latest Funding Round: Post IPO, Jul 17, 2024, $*****
- Highlight: Public
2. MacroGenics
Developer of novel biologics for the treatment of autoimmune disorders, cancer, and infectious disease. The company is developing immune-based products, including monoclonal antibodies and vaccines to prevent infections in healthy individuals. The company’s Fc engineering technology enables to the improvement of antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. Its lead candidate for cancer is Margetuximab, which is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2. HER2 is expressed by tumor cells in the breast, gastroesophageal, bladder, and other forms of solid tumor cancers, making it a key marker for biologic therapy.
Key facts about MacroGenics
- Founded Year: 2000
- Location: Rockville (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $126M
- Employee Count: 332 as on Jul 31, 2026
- Investors: BB Biotech, Saints Capital and 29 Others
- Latest Funding Round: Post IPO, Mar 20, 2019, $*****
- Highlight: Public
Developer of antibody-based drugs for the treatment of solid cancers. The company focuses on the development of a new class of cancer drugs including IMAB362, an antibody-drug candidate for the treatment of gastroesophageal cancer, and IMAB027, a monoclonal antibody to treat ovarian cancer. Its discovery programs are for breast cancer and solid tumors. It also develops Claudetect18.2, a CE marked in vitro diagnostic test to assess the expression levels of claudin-18.2 in the gastroesophageal, pancreatic, lung, and other solid tumors.
Key facts about Ganymed Pharmaceuticals
- Founded Year: 2001
- Location: Mainz (Germany)
- Annual Revenue: €0 - €1M as on Mar 31, 2020
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $212M
- Investors: Nextech Invest, Landesbank Baden Wurttemberg and 8 Others
- Latest Funding Round: Series E, Nov 18, 2013, $*****
- Highlight: Acquired
4. Agensys
Developer of human monoclonal antibodies (MAbs) to treat cancers. It develops products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. It is currently developing a pipeline of therapeutic fully human monoclonal antibodies (mAbs) to treat cancer.
Key facts about Agensys
- Founded Year: 1997
- Location: Santa Monica (United States)
- Stage: Acquired
- Total Funding till date: $84.1M
- Investors: Icon Ventures, Orbimed and 13 Others
- Latest Funding Round: Series D, Jul 12, 2007, $*****
- Highlight: Acquired
Sunesis is developing small molecule therapeutics for solid and hematological cancers. The company has four main candidates in various stages of clinical development. Vosaroxin, (a derivative of the antibacterial agent quinolone), had failed Phase 3 trials for relapsed acute myeloid leukemia. The company's current candidates are kinase inhibitors, the lead among which is SNS-062 (BTK inhibitor) for B-cell malignancies which is undergoing Phase 2 trials. In addition, Sunesis also has another candidate in Phase II clinical testing, for the treatment of solid tumors in partnership with Millenium/ Takeda, and two drugs in preclinical testing.
Key facts about Sunesis Pharmaceuticals
- Founded Year: 1998
- Location: San Francisco (United States)
- Annual Revenue: $0 - $1M as on Dec 31, 2020
- Stage: Public
- Employee Count: 40 as on Jul 31, 2026
- Investors: Ignite 500, Western Alliance Bank and 16 Others
- Latest Funding Round: Venture Debt, Jan 04, 2016, $*****
- Highlight: Public
Nextech Venture's Year-on-Year Investment Trends
Nextech Venture has invested in 8 companies over the last 21 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in Alumis.Nextech Venture's Investments by Stage
Nextech Venture has made 2 investments in Series A stage with an average round size of $14M, 2 investments in Series D stage with an average round size of $33.2M and 1 investment in Post IPO stage with an average round size of $10M.Stage of entry | No. of Investments |
|---|---|
Series A | 2 |
Series D | 2 |
Post IPO | 1 |
Seed | 1 |
Series B | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Nextech Venture's Investments by Sector
Nextech Venture has a diverse portfolio, with companies operating in the Life Sciences, Consumer, High Tech and Media & Entertainment. Notably, it has invested in 8 Tech companies, 5 Enterprise (B2B) companies, 2 Consumer (B2C) companies and at least 2 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 7 |
Consumer | 1 |
High Tech | 1 |
Media & Entertainment | 1 |
Note: We have considered here, only first round of investments
Nextech Venture's Investments by Geography
Nextech Venture has made most investments in United States (5), followed by Germany where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 5 |
Germany | 1 |
Switzerland | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Nextech Venture's recent investments
Nextech Venture has not made any investment in 2026 so far.Here are the most recent investments by Nextech Venture:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 07, 2024 | United States | Series C | 5751 | [+10] | |
Oct 24, 2014 | United Kingdom | Seed | 2410 | [+2] | |
May 19, 2009 | United States | Series A | 9287 | [+5] | |
Apr 16, 2009 | United States | Post IPO | 5605 | [+7] | |
Sep 25, 2008 | United States | Series D | 2784 | [+13] |
IPOs and Publicly Listed companies in Nextech Venture's Portfolio
3 of Nextech Venture's portfolio companies have become public. Alumis got listed on the New York Stock Exchange (NYSE), in Jun 2024 at marketcap of $902M and MacroGenics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $384M.Here are Nextech Venture's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 28, 2024 | Mar 07, 2024 | Series C | 8891 | |
Oct 10, 2013 | Sep 25, 2008 | Series D | 5810 | |
Sep 30, 2005 | Apr 16, 2009 | Post IPO | 8981 |
Acquired companies in Nextech Venture's Portfolio
3 companies from Nextech Venture's portfolio have been acquired. The most recent acquisition was Ganymed Pharmaceuticals in Dec 2016 by Astellas Pharma for $*****.Here are Nextech Venture's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 21, 2016 | Jul 06, 2005 | Series B | 6371 | |
Jun 01, 2015 | Oct 24, 2014 | Seed | 9444 | |
Nov 26, 2007 | Jul 12, 2007 | Series D | 3819 |
Co-investors of Nextech Venture
Over the past 21 years, 70 investors have co-invested in Nextech Venture's portfolio companies. This includes funds and angels.
- Invested before Nextech Venture: Alta Partners, Orbimed and 25 others have invested in rounds before Nextech Venture. There are 2 companies where Alta Partners has invested before Nextech Venture and 2 companies where Orbimed has invested before Nextech Venture.
- Top Co-investors of Nextech Venture: 36 investors entered a company along with Nextech Venture. These include investors like HBM Healthcare Investments (2 companies).
- Invested after Nextech Venture: A total of 7 investors have invested in Nextech Venture's portfolio after their investments. Top Investors include NIH (1 company), BB Biotech (1 company) and MIG Capital (1 company).
Recent News related to Nextech Venture
•
Sprung From The Ashes Of Formspring, Spring.me Raises $5M To Create The “Friendliest Social Network”TechCrunch+•Oct 24, 2014•Spring.me, Right Click Capital, Tank Stream Ventures, Nextec and 2 others
•
Agensys Gets $41.3M - PE HubPE Hub•Jul 14, 2007•Agensys, Nextech Venture, Bear Stearns Companies, Alta Partners and 3 others
•
MacroGenics Raises $25M in Series D-2 Financing | MacroGenics, Inc.MacroGenics•MacroGenics, Nextech Venture, Arcus Ventures, Lilly and 12 others
